ArticleInfection2026
Hyper-activated low-density neutrophil-derived NGAL predicts fatal SFTS: a multi-cohort and single-cell study.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeSevere fever with thrombocytopenia syndrome (SFTS) is an acute infectious disease with rapid progression and high mortality. This study aimed to assess the predictive power of serum neutrophil gelatinase-associated lipocalin (NGAL) for mortality risk and elucidate its cellular origin at the single-cell level.
methodsIn this retrospective multicenter study, we analyzed clinical data from 215 SFTS patients across three Chinese hospitals (152 in the training cohort and 63 in the external validation cohort). We further analyzed publicly available single-cell RNA sequencing (scRNA-seq) data of peripheral blood mononuclear cells (PBMCs) from SFTS patients and healthy controls to investigate the cellular source of NGAL.
resultsSerum NGAL was identified as an independent risk factor for 14-day and 28-day all-cause mortality (P < 0.05). High NGAL levels were linearly associated with increased mortality and remained stable across various clinical subgroups. Crucially, unbiased scRNA-seq analysis revealed that the elevated NGAL (encoded by the LCN2 gene) primarily originated from low-density neutrophils (LDNs) that co-purified with PBMCs. These LCN2-expressing LDNs were highly enriched in non-survivors and exhibited a hyper-inflammatory, interferon-stimulated transcriptomic signature.
conclusionOur findings establish serum NGAL as a robust early predictor of mortality risk in SFTS patients, with its elevation intrinsically linked to the pathogenic emergence of highly activated LDNs, providing novel insights into the immunopathology of fatal SFTS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.